HuR suppresses fas expression and correlates with patient outcome in liver cancer

Molecular Cancer Research

Volumn 13, Issue 5, 2015, Pages 809-818

  Zhu, Haifeng ^a   Berkova, Zuzana ^a   Mathur, Rohit ^a   Sehgal, Lalit ^a   Khashab, Tamer ^a   Tao, Rong Hua ^a   Ao, Xue ^a   Feng, Lei ^a   Sabichi, Anita L ^b   Blechacz, Boris ^a   Rashid, Asif ^a   Samaniego, Felipe ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; HUR PROTEIN; MESSENGER RNA; RIBONUCLEOPROTEIN; ELAV LIKE PROTEIN 1; ELAVL1 PROTEIN, HUMAN; FAS LIGAND; FASLG PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ADULT; AGED; APOPTOSIS; ARTICLE; BINDING SITE; CELL SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDRODYNAMICS BASED TRANSFECTION; LIVER CANCER CELL LINE; LIVER CELL CARCINOMA; MALE; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA TRANSLATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; C57BL MOUSE; CELL DEATH; CELL SURVIVAL; DEFICIENCY; GENE SILENCING; GENETIC TRANSFECTION; GENETICS; LIVER TUMOR; METABOLISM; MOUSE; PATHOLOGY; PHYSIOLOGY; PROTEIN SYNTHESIS; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD95; CARCINOMA, HEPATOCELLULAR; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; ELAV-LIKE PROTEIN 1; FAS LIGAND PROTEIN; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; PROTEIN BIOSYNTHESIS; RNA, MESSENGER; TRANSFECTION;

EID: 84942310344     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-14-0241     Document Type: Article

References (36)

1. Blechacz B, Mishra L. Hepatocellular carcinoma biology. Recent Results Cancer Res 2013;190:1-20.
2. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27:1485-91.
3. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533-43.
4. Nagao M, Nakajima Y, Hisanaga M, Kayagaki N, Kanehiro H, Aomatsu Y, et al. The alteration of Fas receptor and ligand system in hepatocellular carcinomas: how do hepatoma cells escape from the host immune surveillance in vivo? Hepatology 1999;30:413-21.
5. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3:991-8.
6. Kubo K, Matsuzaki Y, Okazaki M, Kato A, Kobayashi N, Okita K. The Fas system is not significantly involved in apoptosis in human hepatocellular carcinoma. Liver 1998;18:117-23.
7. Izquierdo JM. Cell-specific regulation of Fas exon 6 splicing mediated by Hu antigen R. Biochem Biophys Res Commun 2010;402: 324-8.
8. Brennan CM, Steitz JA. HuR and mRNA stability. Cell Mol Life Sci 2001;58:266-77.
9. Abdelmohsen K, Gorospe M. Posttranscriptional regulation of cancer traits by HuR. Wiley Interdiscip Rev RNA 2010;1:214-29.
10. Izquierdo JM. Hu antigen R (HuR) functions as an alternative pre-mRNA splicing regulator of Fas apoptosis-promoting receptor on exon definition. J Biol Chem 2008;283:19077-84.
11. Alvarez E, Castello A, Carrasco L, Izquierdo JM. Poliovirus 2A protease triggers a selective nucleo-cytoplasmic redistribution of splicing factors to regulate alternative pre-mRNA splicing. PloS ONE 2013;8: e73723.
12. Wise JF, Berkova Z, Mathur R, Zhu H, Braun FK, Tao RH, et al. Nucleolin inhibits Fas ligand binding and suppresses Fas-mediated apoptosis in vivo via a surface nucleolin-Fas complex. Blood 2013;121:4729-39.
13. Berkova Z, Wang S, Wise JF, MaengH, Ji Y, Samaniego F. Mechanism of Fas signaling regulation by human herpesvirus 8 K1 oncoprotein. JNatl Cancer Inst 2009;101:399-411.
14. Tao RH, Berkova Z, Wise JF, Rezaeian AH, Daniluk U, Ao X, et al. PMLRARalpha binds to Fas and suppresses Fas-mediated apoptosis through recruiting c-FLIP in vivo. Blood 2011;118:3107-18.
15. Vazquez-Chantada M, Fernandez-Ramos D, Embade N, Martinez-Lopez N, Varela-Rey M, Woodhoo A, et al. HuR/methyl-HuR and AUF1 regulate the MAT expressed during liver proliferation, differentiation, and carcinogenesis. Gastroenterology 2010;138:1943-53.
16. Drury GL, Di Marco S, Dormoy-Raclet V, Desbarats J, Gallouzi IE. FasL expression in activated T lymphocytes involves HuR-mediated stabilization. J Biol Chem 2010;285:31130-8.
17. Katsanou V, Papadaki O, Milatos S, Blackshear PJ, Anderson P, Kollias G, et al. HuR as a negative posttranscriptional modulator in inflammation. Molecular cell 2005;19:777-89.
18. Ronkainen H, Vaarala MH, Hirvikoski P, Ristimaki A. HuR expression is a marker of poor prognosis in renal cell carcinoma. Tumour Biol 2011;32:481-7.
19. Hung CM, Huang WC, Pan HL, Chien PH, Lin CW, Chen LC, et al. Hepatitis B virus X upregulates HuR protein level to stabilize HER2 expression in hepatocellular carcinoma cells. Biomed Res Int 2014; 2014:827415.
20. Embade N, Fernandez-Ramos D, Varela-ReyM, Beraza N, Sini M, Gutierrez de Juan V, et al. Murine doubleminute 2 regulates Hu antigen R stability in human liver and colon cancer through NEDDylation. Hepatology 2012;55:1237-48.
21. Martinez-Lopez N, Varela-Rey M, Fernandez-Ramos D, Woodhoo A, Vazquez-Chantada M, Embade N, et al. Activation of LKB1-Akt pathway independent of phosphoinositide 3-kinase plays a critical role in the proliferation of hepatocellular carcinoma from nonalcoholic steatohepatitis. Hepatology 2010;52:1621-31.
22. Nabors LB, Gillespie GY, Harkins L, King PH. HuR, a RNA stability factor, is expressed in malignant brain tumors and binds to adenine-and uridinerich elements within the 30 untranslated regions of cytokine and angiogenic factor mRNAs. Cancer Res 2001;61:2154-61.
23. Leandersson K, Riesbeck K, Andersson T. Wnt-5a mRNA translation is suppressed by the Elav-like protein HuR in human breast epithelial cells. Nucleic Acids Res 2006;34:3988-3999.
24. Abdelmohsen K, Lal A, Kim HH, Gorospe M. Posttranscriptional orchestration of an anti-apoptotic program by HuR. Cell Cycle 2007; 6:1288-92.
25. Wang W, Furneaux H, Cheng H, Caldwell MC, Hutter D, Liu Y, et al. HuR regulates p21 mRNA stabilization by UV light. Mol Cell Biol 2000;20: 760-9.
26. Hammam O, Mahmoud O, Zahran M, Aly S, Hosny K, Helmy A, et al. The role of fas/fas ligand system in the pathogenesis of liver cirrhosis and hepatocellular carcinoma. Hep Monthly 2012;12: e6132.
27. Ito Y, Monden M, Takeda T, Eguchi H, Umeshita K, Nagano H, et al. The status of Fas and Fas ligand expression can predict recurrence of hepatocellular carcinoma. Br J Cancer 2000;82:1211-7.
28. Roskams T, Libbrecht L, Van Damme B, Desmet V. Fas and Fas ligand: strong co-expression in human hepatocytes surrounding hepatocellular carcinoma; can cancer induce suicide in peritumoural cells? J Pathol 2000;191:150-3.
29. Wang X, Liu Y. Regulation of innate immune response by MAP kinase phosphatase-1. Cell Signal 2007;19:1372-82.
30. Beck C, Schreiber H, Rowley D. Role of TGF-beta in immune-evasion of cancer. Microsc Res Tech 2001;52:387-95.
31. Meisner NC, Hintersteiner M, Mueller K, Bauer R, Seifert JM, Naegeli HU, et al. Identification and mechanistic characterization of low-molecular-weight inhibitors for HuR. Nat Chem Biol 2007; 3:508-15.
32. SunDQ, WangY, Liu DG. Cancer cell growth suppression by a 62nt AU-rich RNA from C/EBPbeta 30UTR through competitive binding with HuR. Biochem Biophys Res Commun 2012;426:122-8.
33. Siddiqui N, Borden KL. mRNA export and cancer. Wiley Interdiscip Rev RNA 2012;3:13-25.
34. Wang W, Caldwell MC, Lin S, Furneaux H, Gorospe M.HuRregulates cyclin A and cyclin B1 mRNA stability during cell proliferation. EMBO J 2000;19:2340-50
35. Levy NS, Chung S, Furneaux H, Levy AP. Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J Biol Chem 1998;273:6417-23.
36. Sheflin LG, Zou AP, Spaulding SW. Androgens regulate the binding of endogenous HuR to the AU-rich 30UTRs of HIF-1alpha and EGF mRNA. Biochem Biophys Res Commun 2004;322:644-51.